Advertisement
U.S. markets close in 2 hours 44 minutes
Advertisement

Certara, Inc. (CERT)

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
Visitors trend2W10W9M
14.69-0.03 (-0.20%)
As of 01:15PM EST. Market open.
Full screen
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Bearishpattern detected
Momentum

Momentum

Performance Outlook
Previous Close14.72
Open14.52
Bid14.61 x 800
Ask14.62 x 800
Day's Range14.39 - 14.73
52 Week Range11.81 - 24.96
Volume382,180
Avg. Volume671,477
Market Cap2.348B
Beta (5Y Monthly)1.57
PE Ratio (TTM)N/A
EPS (TTM)-0.22
Earnings DateFeb 28, 2024 - Mar 04, 2024
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est17.14
Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected.
Fair Value
XX.XX
Overvalued
-47% Est. Return

Subscribe to Yahoo Finance Plus to view Fair Value for CERT

View details
Research that delivers an independent perspective, consistent methodology and actionable insight
Related Research
  • Certara, Inc.
    Daily – Vickers Top Buyers & Sellers for 11/17/2022The Vickers Top Buyers & Sellers is a daily report that identifies the five companies the largest insider purchase transactions based on the dollar value of the transactions as well as the five companies the largest insider sales transactions based on the dollar value of the transactions.
    Rating
    Fair Value
    Economic Moat
    last yearArgus Research
View more
  • GlobeNewswire

    Certara introduces Simcyp™ Biopharmaceutics software to increase efficiency of novel and generic drug formulation & development

    Simcyp Biopharmaceutics helps drug developers replace costly clinical bioequivalence studies and optimize formulations for complex therapiesPRINCETON, N.J., Nov. 21, 2023 (GLOBE NEWSWIRE) -- Certara, Inc. (Nasdaq: CERT), a global leader in biosimulation, today announced the introduction of Simcyp™ Biopharmaceutics software. It is designed for use by biopharmaceutic, formulation, and CMC scientists to aid in formulating complex novel and generic small molecule medicines quickly and cost effective

  • Insider Monkey

    Certara, Inc. (NASDAQ:CERT) Q3 2023 Earnings Call Transcript

    Certara, Inc. (NASDAQ:CERT) Q3 2023 Earnings Call Transcript November 8, 2023 Certara, Inc. reports earnings inline with expectations. Reported EPS is $0.11 EPS, expectations were $0.11. Operator: Good day, and thank you for standing by. Welcome to the Certara Third Quarter 2023 Earnings Conference Call. [Operator Instructions] Please be advised that today’s conference is being […]

  • Thomson Reuters StreetEvents

    Q3 2023 Certara Inc Earnings Call

    Q3 2023 Certara Inc Earnings Call